USRE48890EExpiredUtilityPatentIndex 63
Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
Est. expiryMay 17, 2022(expired)· nominal 20-yr term from priority
Inventors:ZELDIS JEROME B
G01N 33/57585G01N 33/57555G01N 33/57535G01N 33/5759G01N 33/5758G01N 33/5752G01N 33/575A61K 31/4439A61P 35/00A61K 38/00C07K 14/4748G01N 33/5082C12Q 2600/136C07K 14/705G01N 2500/00C07K 2319/30A01K 2227/105A01K 2217/075C12Q 1/6816C12Q 1/6886C07K 16/28C07K 14/47C12Q 1/6883C07K 14/82G01N 33/5308C12Q 2600/158G01N 33/57423C12Q 2563/131G01N 33/57492G01N 33/57434G01N 33/574C12Q 2527/137G01N 33/57488G01N 33/57419G01N 33/57484
63
PatentIndex Score
0
Cited by
706
References
34
Claims
Abstract
Methods of treating, preventing and/or managing cancer as well as and diseases and disorder associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1. A method of treating multiple myeloma, the method comprising administering to a patient having multiple myeloma about 1 to about 50 mg per day of a compound having the formula:
or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, and a therapeutically effective amount of biaxin, busulphan, or celecoxib, wherein the patient has previously received hematopoietic stem cell transplantation.
2. The method of claim 1 , wherein the multiple myeloma is relapsed, refractory, or relapsed and refractory multiple myeloma.
3. The method of claim 1 , wherein the compound is administered for 21 consecutive days followed by seven consecutive days of rest in a 28 day cycle.
4. The method of claim 1 , wherein the compound is administered every day.
5. The method of claim 1 , wherein the compound is administered orally.
6. The method of claim 1 , wherein the compound is administered in the form of a capsule or tablet.
7. The method of claim 1 , wherein the compound is administered in a capsule of 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg or 25 mg.
8. The method of claim 6 , wherein the capsule comprises the compound, lactose anhydrous, microcrystalline cellulose, croscarmellose sodium and magnesium stearate.
9. The method of claim 1 , wherein the compound is administered in an amount of about 25 mg per day.
10. The method of claim 1 , wherein the compound is administered in an amount of about 20 mg per day.
11. The method of claim 1 , wherein the compound is administered in an amount of about 15 mg per day.
12. The method of claim 1 , wherein the compound is administered in an amount of about 10 mg per day.
13. The method of claim 1 , wherein the compound is administered in an amount of about 5 mg per day.
14. The method of claim 1 , wherein the compound is administered in an amount of about 2.5 mg per day.
15. The method of claim 3 , wherein the compound is administered in an amount of about 25 mg per day.
16. The method of claim 4 , wherein the compound is administered in an amount of about 5 mg, 10 mg or 15 mg per day.
17. The method of claim 1 , wherein the compound is administered in a capsule containing from about 1 mg to about 50 mg of the compound.
18. A method of treating multiple myeloma, the method comprising administering to a patient having multiple myeloma about 1 to about 50 mg per day of a compound having the formula:
or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, and a therapeutically effective amount of biaxin, busulphan, or celecoxib, wherein the patient has previously received autologous stem cell transplantation.
19. The method of claim 18 , wherein the multiple myeloma is relapsed, refractory, or relapsed and refractory multiple myeloma.
20. The method of claim 18 , wherein the compound is administered for 21 consecutive days followed by seven consecutive days of rest in a 28 day cycle.
21. The method of claim 18 , wherein the compound is administered every day.
22. The method of claim 18 , wherein the compound is administered orally.
23. The method of claim 18 , wherein the compound is administered in the form of a capsule or tablet.
24. The method of claim 18 , wherein the compound is administered in a capsule of 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg or 25 mg.
25. The method of claim 24 , wherein the capsule comprises the compound, lactose anhydrous, microcrystalline cellulose, croscarmellose sodium and magnesium stearate.
26. The method of claim 18 , wherein the compound is administered in an amount of about 25 mg per day.
27. The method of claim 18 , wherein the compound is administered in an amount of about 20 mg per day.
28. The method of claim 18 , wherein the compound is administered in an amount of about 15 mg per day.
29. The method of claim 18 , wherein the compound is administered in an amount of about 10 mg per day.
30. The method of claim 18 , wherein the compound is administered in an amount of about 5 mg per day.
31. The method of claim 18 , wherein the compound is administered in an amount of about 2.5 mg per day.
32. The method of claim 20 , wherein the compound is administered in an amount of about 25 mg per day.
33. The method of claim 21 , wherein the compound is administered in an amount of about 5 mg, 10 mg or 15 mg per day.
34. The method of claim 18 , wherein the compound is administered in a capsule containing from about 1 mg to about 50 mg of the compound.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.